Similar articles for PMID: 34969761

Year	Number of Results
2004	1
2005	1
2009	1
2010	2
2011	1
2012	4
2013	5
2014	4
2015	4
2016	10
2017	13
2018	15
2019	8
2020	19
2021	16
2022	6
2023	2
2024	0

1

Epstein-Barr Virus-induced Gene 3 as a Novel Biomarker in Metastatic Melanoma With Infiltrating CD8⁺ T Cells: A Study Based on The Cancer Genome Atlas (TCGA).

Yonekura S. Yonekura S. Anticancer Res. 2022 Jan;42(1):511-517. doi: 10.21873/anticanres.15509. Anticancer Res. 2022. PMID: 34969761

2

The role of tumor-infiltrating lymphocytes (TILs) as a predictive biomarker of response to anti-PD1 therapy in patients with metastatic non-small cell lung cancer or metastatic melanoma.

Uryvaev A, Passhak M, Hershkovits D, Sabo E, Bar-Sela G. Uryvaev A, et al. Med Oncol. 2018 Jan 31;35(3):25. doi: 10.1007/s12032-018-1080-0. Med Oncol. 2018. PMID: 29388007

3

EVI2B Is a New Prognostic Biomarker in Metastatic Melanoma with IFNgamma Associated Immune Infiltration.

Yonekura S, Ueda K. Yonekura S, et al. Cancers (Basel). 2021 Aug 15;13(16):4110. doi: 10.3390/cancers13164110. Cancers (Basel). 2021. PMID: 34439264 Free PMC article.

4

Inflammatory cell infiltrates in advanced metastatic uveal melanoma.

Krishna Y, McCarthy C, Kalirai H, Coupland SE. Krishna Y, et al. Hum Pathol. 2017 Aug;66:159-166. doi: 10.1016/j.humpath.2017.06.005. Epub 2017 Jun 24. Hum Pathol. 2017. PMID: 28655639

5

Genome-wide DNA methylation profile analysis identifies an individualized predictive signature for melanoma immune response.

Yan J, Wu X, Zhu Y, Cang S. Yan J, et al. J Cancer Res Clin Oncol. 2023 Jan;149(1):343-356. doi: 10.1007/s00432-022-04566-1. Epub 2023 Jan 3. J Cancer Res Clin Oncol. 2023. PMID: 36595044

6

Data mining of immune-related prognostic genes in metastatic melanoma microenvironment.

Han W, Huang B, Zhao XY, Shen GL. Han W, et al. Biosci Rep. 2020 Nov 27;40(11):BSR20201704. doi: 10.1042/BSR20201704. Biosci Rep. 2020. PMID: 33169786 Free PMC article.

7

Predicting the clinical outcome of melanoma using an immune-related gene pairs signature.

Meng L, He X, Zhang X, Zhang X, Wei Y, Wu B, Li W, Li J, Xiao Y. Meng L, et al. PLoS One. 2020 Oct 8;15(10):e0240331. doi: 10.1371/journal.pone.0240331. eCollection 2020. PLoS One. 2020. PMID: 33031392 Free PMC article.

8

Immunologic heterogeneity of tumor-infiltrating lymphocyte composition in primary melanoma.

Weiss SA, Han SW, Lui K, Tchack J, Shapiro R, Berman R, Zhong J, Krogsgaard M, Osman I, Darvishian F. Weiss SA, et al. Hum Pathol. 2016 Nov;57:116-125. doi: 10.1016/j.humpath.2016.07.008. Epub 2016 Jul 26. Hum Pathol. 2016. PMID: 27473267 Free PMC article.

9

Prognostic perspectives of PD-L1 combined with tumor-infiltrating lymphocytes, Epstein-Barr virus, and microsatellite instability in gastric carcinomas.

Choi E, Chang MS, Byeon SJ, Jin H, Jung KC, Kim H, Lee KL, Kim W, Park JH, Kim KH, Kim JS, Choi IS, Han DS, Ahn HS, Heo SC. Choi E, et al. Diagn Pathol. 2020 Jun 4;15(1):69. doi: 10.1186/s13000-020-00979-z. Diagn Pathol. 2020. PMID: 32498695 Free PMC article.

10

Randomized selection design trial evaluating CD8+-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma.

Dudley ME, Gross CA, Somerville RP, Hong Y, Schaub NP, Rosati SF, White DE, Nathan D, Restifo NP, Steinberg SM, Wunderlich JR, Kammula US, Sherry RM, Yang JC, Phan GQ, Hughes MS, Laurencot CM, Rosenberg SA. Dudley ME, et al. J Clin Oncol. 2013 Jun 10;31(17):2152-9. doi: 10.1200/JCO.2012.46.6441. Epub 2013 May 6. J Clin Oncol. 2013. PMID: 23650429 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

104 results

Results by year